Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0149871 (
deep vein thrombosis
)
12,364
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Deep vein thrombosis (DVT)
with its major complication, pulmonary embolism, is a global health problem. Mechanisms of
DVT
remain incompletely understood. Platelets play a role in
DVT
, but the impact of specific platelet receptors remains unclear. Platelet C-type lectin-like receptor 2 (CLEC-2) is known to maintain the physiological state of blood vasculature under inflammatory conditions.
DVT
is a thromboinflammatory disorder developing largely as sterile inflammation in the vessel wall. We hypothesized therefore that CLEC-2 might play a role in
DVT
. Here, using a murine
DVT
model of inferior vena cava (IVC) stenosis, we demonstrate that mice with general inducible deletion of CLEC-2 or platelet-specific deficiency in CLEC-2 are protected against
DVT
. No phenotype in the complete stasis model was observed. Transfusion of wild-type platelets into platelet-specific CLEC-2 knockout mice restored thrombosis. Deficiency in CLEC-2 as well as inhibition of
podoplanin
, a ligand of CLEC-2, was associated with reduced platelet accumulation at the IVC wall after 6 hours of stenosis.
Podoplanin
was expressed in the IVC wall, where it was localized in the vicinity of the abluminal side of the endothelium. The level of
podoplanin
in the IVC increased after 48 hours of stenosis to a substantially higher extent in mice with a thrombus vs those without a thrombus. Treatment of animals with an anti-
podoplanin
neutralizing antibody resulted in development of smaller thrombi. Thus, we propose a novel mechanism of
DVT
, whereby CLEC-2 and upregulation of
podoplanin
expression in the venous wall trigger thrombus formation.
...
PMID:Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis. 2838 72
C-type lectin-like receptor 2 (CLEC-2) has been identified on the surface of platelets as a receptor for a platelet activating snake venom, rhodocytin/aggretin. CLEC-2 belongs to a C-type lectin superfamily and binds to a sialoglycoprotein,
podoplanin
, in vivo. Platelets play a crucial role in hemostasis and thrombosis, but recent studies have uncovered multiple roles of platelets beyond hemostasis in physiology and pathology. The interaction between platelet CLEC-2 and
podoplanin
is the key to several roles of platelets beyond hemostasis. The spatial and temporal expression patterns of
podoplanin
regulate vascular/lymphatic development, maintenance of vascular integrity, tissue regeneration, and some pathological processes including tumor metastasis and thromboinflammation. CLEC-2 facilitates blood/lymphatic vessel separation during embryonic development by binding to
podoplanin
on lymphatic endothelial cells. The leakage of platelets from hyperpermeable vessels for maintaining vascular integrity during inflammation depends on CLEC-2. During wound healing, the expression of
podoplanin
in keratinocytes is upregulated, which helps in the process.
Podoplanin
is expressed on the surface of tumor cells and facilitates hematogenous metastasis by inducing platelet aggregation through CLEC-2. During thrombotic processes, such as development of
deep vein thrombosis
,
podoplanin
is upregulated on unknown cells in the vessel wall in the area of inflammation, facilitates thrombus formation, and promotes further inflammation by binding to CLEC-2. In this article, the roles of platelets beyond hemostasis are comprehensively reviewed.
...
PMID:Platelet CLEC-2: Roles Beyond Hemostasis. 2899 50